PubRank

Roger L Williams

Author PubWeight™ 120.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006 10.06
3 Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007 5.19
4 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008 3.84
5 Structural basis for selective recognition of ESCRT-III by the AAA ATPase Vps4. Nature 2007 3.47
6 Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 2013 3.33
7 Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science 2010 3.20
8 The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 2010 3.15
9 A role for the ESCRT system in cell division in archaea. Science 2008 2.94
10 ESCRT-II, an endosome-associated complex required for protein sorting: crystal structure and interactions with ESCRT-III and membranes. Dev Cell 2004 2.86
11 Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell 2011 2.50
12 ESCRT-I core and ESCRT-II GLUE domain structures reveal role for GLUE in linking to ESCRT-I and membranes. Cell 2006 2.38
13 Binding of the PX domain of p47(phox) to phosphatidylinositol 3,4-bisphosphate and phosphatidic acid is masked by an intramolecular interaction. EMBO J 2002 2.09
14 Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci U S A 2012 2.04
15 Structure and disassembly of filaments formed by the ESCRT-III subunit Vps24. Structure 2008 1.95
16 PB1 domain-mediated heterodimerization in NADPH oxidase and signaling complexes of atypical protein kinase C with Par6 and p62. Mol Cell 2003 1.78
17 Structural basis for Arl1-dependent targeting of homodimeric GRIP domains to the Golgi apparatus. Mol Cell 2003 1.70
18 Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal 2011 1.68
19 Structural insight into the ESCRT-I/-II link and its role in MVB trafficking. EMBO J 2007 1.60
20 Structural insights into endosomal sorting complex required for transport (ESCRT-I) recognition of ubiquitinated proteins. J Biol Chem 2004 1.57
21 Structural role of Sfi1p-centrin filaments in budding yeast spindle pole body duplication. J Cell Biol 2006 1.51
22 Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α. Structure 2011 1.48
23 Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash) 2002 1.46
24 Balancing efficacy and safety in the use of oral sedation in dental outpatients. J Am Dent Assoc 2006 1.42
25 Structure of a human inositol 1,4,5-trisphosphate 3-kinase: substrate binding reveals why it is not a phosphoinositide 3-kinase. Mol Cell 2004 1.39
26 G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness. Sci Signal 2012 1.38
27 Application of USP-NF Standard to Pharmacy Compounding. Int J Pharm Compd 2013 1.27
28 Structural and membrane binding analysis of the Phox homology domain of Bem1p: basis of phosphatidylinositol 4-phosphate specificity. J Biol Chem 2007 1.22
29 The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance. Pharm Res 2008 1.13
30 Toward global standards for comparator pharmaceutical products: case studies of amoxicillin, metronidazole, and zidovudine in the Americas. AAPS J 2012 1.12
31 Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 2007 1.11
32 The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain. Structure 2012 1.09
33 Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc Natl Acad Sci U S A 2013 1.06
34 Structural and membrane binding analysis of the Phox homology domain of phosphoinositide 3-kinase-C2alpha. J Biol Chem 2006 1.05
35 Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv Biol Regul 2012 1.05
36 Molecular and structural basis of ESCRT-III recruitment to membranes during archaeal cell division. Mol Cell 2011 1.03
37 The role of phosphoinositides and phosphorylation in regulation of NADPH oxidase. Adv Enzyme Regul 2004 1.02
38 Structural studies of phosphoinositide 3-kinase-dependent traffic to multivesicular bodies. Biochem Soc Symp 2007 0.99
39 Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi. Nature 2013 0.98
40 The USP Performance Verification Test, Part II: collaborative study of USP's Lot P Prednisone Tablets. Pharm Res 2008 0.94
41 The barrier to enantiomerization of N-Boc-2-lithiopyrrolidine: the effect of chiral and achiral diamines. Chem Commun (Camb) 2008 0.93
42 Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. Food Drug Law J 2008 0.93
43 The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 2010 0.92
44 A segment of cold shock protein directs the folding of a combinatorial protein. Proc Natl Acad Sci U S A 2005 0.91
45 Selected medication-error data from USP's MEDMARX program for 2002. Am J Health Syst Pharm 2004 0.89
46 Improving the safety of neuromuscular blocking agents: a statement from the USP Safe Medication Use Expert Committee. Am J Health Syst Pharm 2006 0.89
47 A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. J Allergy Clin Immunol 2002 0.87
48 The structural basis of novel endosome anchoring activity of KIF16B kinesin. EMBO J 2007 0.86
49 Metal impurities in food and drugs. Pharm Res 2010 0.85
50 Progressively reducing regulatory burden. AAPS J 2014 0.85
51 PKCβ phosphorylates PI3Kγ to activate it and release it from GPCR control. PLoS Biol 2013 0.85
52 Evolution and assembly of ESCRTs. Biochem Soc Trans 2009 0.85
53 ESCRT-III binding protein MITD1 is involved in cytokinesis and has an unanticipated PLD fold that binds membranes. Proc Natl Acad Sci U S A 2012 0.84
54 Weight-loss study in African-American Women: lessons learned from project take HEED and future, technologically enhanced directions. Perm J 2013 0.84
55 FDA's dietary supplement CGMPs: standards without standardization. Food Drug Law J 2008 0.84
56 Establishing new acceptance limits for dissolution performance verification of USPC apparatus 1 and 2 using USPC prednisone tablets reference standard. Pharm Res 2010 0.82
57 Finding a fitting shoe for Cinderella: searching for an autophagy inhibitor. Autophagy 2010 0.81
58 PI3Kβ downstream of GPCRs - crucial partners in oncogenesis. Oncotarget 2012 0.77
59 Ensuring global access to quality medicines: role of the US Pharmacopeia. J Pharm Sci 2010 0.77
60 Connecting with an old partner in a new way. Cancer Cell 2013 0.77
61 The use of a test to determine that consent is informed. Mil Med 1977 0.76
62 Membrane trafficking: Arls squeeze the fat out. Nat Chem Biol 2011 0.75
63 Dietary supplements and regulation. JAMA 2011 0.75
64 Change in criteria for USP dissolution performance verification tests. AAPS PharmSciTech 2009 0.75
65 Allosteric activation of PI3Kα by oncogenic mutations. Oncotarget 2013 0.75
66 Kinases charging to the membrane. Cell 2010 0.75
67 [Roles of ESCRT complexes in the MVB pathway]. Tanpakushitsu Kakusan Koso 2008 0.75
68 Metrologic approaches to setting acceptance criteria: unacceptable and unusual characteristics. J Pharm Biomed Anal 2008 0.75
69 Measurement science for food and drug monographs: toward a global system. Pharm Res 2010 0.75
70 Oral dosage form performance tests: new dissolution approaches. Pharm Res 2005 0.75
71 Structural basis for the interaction of [E160A-E189A]-trichosanthin with adenine. Toxicon 2003 0.75